5 juni 2026 Sweden
BioStock: External proposals are pouring in to Diamyd
Diamyd Medical reports that it has received several external proposals, including Letters of Intent and invitations to invest in various projects, as part of its ongoing strategic review. Following the discontinuation of the Phase III DIAGNODE-3 trial, the company is implementing cost-saving measures and evaluating strategic alternatives under the leadership of founder and CEO Anders Essen-Möller.
Read the article here
Information som presenteras här är inte pressmeddelanden och kan innehålla utdrag ur och länkar till externt publicerat innehåll. Diamyd Medical ansvarar inte för externt publicerat innehåll.